Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
whole virion inactivated vaccine against clade 2.3.4.4b H5N1 influenza virus
- Development stage
- Unknown
- Lead developer
- Seoul National University
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal, Intramuscular, Subcutaneous
01
Overview
This drug is a whole virion inactivated vaccine developed to combat the highly pathogenic avian influenza (HPAI) H5N1 virus, specifically targeting clade 2.3.4.4b. It is designed to induce a robust immune response by presenting inactivated, intact virus particles to the immune system. The vaccine aims to stimulate both humoral (antibody-mediated) and cellular (T-cell-mediated) immunity, providing protection against H5N1 infection and its associated disease. Research indicates its potential for cross-protection against both homologous and heterologous H5N1 strains. Some formulations are being explored for intranasal administration, with efforts to optimize antigen stability and immunogenicity. It is being developed for both human pandemic preparedness and veterinary applications, particularly in poultry.
- Other names
- whole inactivated virus (WIV) vaccine against clade 2.3.4.4b H5N1 influenza viruswhole-virus particle vaccine (WPV) against clade 2.3.4.4b H5N1 influenza virus
02
Targets
H1 HA (Influenza A hemagglutinin H1)Neuraminidase
Beyond the preview
Go deeper on whole virion inactivated vaccine against clade 2.3.4.4b H5N1 influenza virus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on whole virion inactivated vaccine against clade 2.3.4.4b H5N1 influenza virus.